Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Commercial DEFINITY® to Monitor the Effects of the Heart`s Pulmonary Artery Pressure

Study:

A Phase IV, Open-Label Safety Evaluation of the Effect of DEFINITY® on Pulmonary Artery Hemodynamics in Patients With Normal and Increased Pulmonary Artery Pressure

Rationale:

n/a

Purpose:

The purpose of this clinical research is to learn if DEFINITY® 416 will cause any adverse effects during Right Heart Catheterization. This research was requested by the FDA.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Pulmonary Heart Disease Drug: Definity Phase 4

Verified by Lantheus Medical Imaging October, 2011

Sponsored by: Lantheus Medical Imaging
Information provided by: Lantheus Medical Imaging
ClinicalTrials.gov identifier: NCT00918866

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Veronica Lee, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site